Trials / Completed
CompletedNCT00318656
24-Hour Glycemia: Rosiglitazone Versus Glimepiride In Type 2 Diabetes
Comparison of the Effects of Rosiglitazone and Glimepiride, Both Given in Combination With Metformin, on 24-Hour Glycemia in Type 2 Diabetes Patients Not Controlled With Metformin Alone. A 3-Month Multicentre, Randomized, Parallel-Group, Open-Label Study.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 40 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A better glycemic control is associated with less complications (cardiac diseases, blindness, etcetera) for type 2 diabetic patients. The objective is to study if rosiglitazone may lead to a more regular glycemic pattern with less hyperglycemia and hypoglycemia episodes than with a sulphonylurea (glimepiride).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | rosiglitazone-metformin fixed dose combination | |
| DRUG | metformin + glimepiride |
Timeline
- Start date
- 2005-11-01
- Primary completion
- 2007-10-01
- Completion
- 2007-10-01
- First posted
- 2006-04-27
- Last updated
- 2009-05-07
- Results posted
- 2009-03-18
Source: ClinicalTrials.gov record NCT00318656. Inclusion in this directory is not an endorsement.